Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.165
+0.065 (5.91%)
Feb 5, 2026, 1:06 PM EST - Market open

Enlivex Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
277265072115121
Market Cap Growth
956.84%-48.77%-30.73%-36.72%-5.58%39.92%
Enterprise Value
265224203394
Last Close Price
1.101.172.703.946.258.43
PB Ratio
1.531.091.671.271.353.42
P/TBV Ratio
16.161.091.671.271.353.42
Debt / Equity Ratio
0.040.020.030.090.070.02
Quick Ratio
6.266.564.557.7018.098.17
Current Ratio
6.436.845.577.9218.328.72
Return on Equity (ROE)
-57.64%-55.95%-66.88%-43.78%-24.01%-50.56%
Return on Assets (ROA)
-36.02%-30.10%-30.09%-19.81%-17.79%-21.12%
Return on Capital Employed (ROCE)
-81.60%-65.00%-81.70%-42.30%-21.30%-27.20%
Earnings Yield
-4.50%-58.36%-57.89%-42.84%-12.63%-9.74%
FCF Yield
-4.24%-50.96%-47.31%-44.24%-16.73%-9.91%
Buyback Yield / Dilution
-20.50%-10.44%-0.98%-3.00%-35.62%-52.25%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q